NCT06711991 - A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 11, 2025

Primary Completion Date

August 11, 2025

Study Completion Date

August 11, 2025

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

TQC3927 powder for inhalation

TQC3927 is a targeted inhibitor

DRUG

TQC3927 powder for inhalation placebo

A placebo without drug substance.

Trial Locations (7)

China Japan Friendship Hospital, Beijing

Aerospace Center Hospital, Beijing

Zibo Municipal Hospital, Zibo

Heze Municipal Hospital, Heze

The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou

The First Affiliated Hospital of Nanchang University, Nanchang

The Third People Hospital of Chengdu, Chengdu